Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Cancer vaccines aim to stimulate T cell responses against tumors.
• Current peptide-based cancer vaccines often show limited clinical efficacy.
• Understanding T cell behavior post-vaccination is crucial for improving cancer immunotherapy.

Purpose of the Study:

• To investigate the reasons behind the frequent failure of cancer vaccine-induced T cells to eradicate tumors.
• To analyze the immune response dynamics in mice vaccinated with a common peptide/adjuvant formulation.

Main Methods:

• Vaccination of mice with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA).
• Analysis of CD8(+) T cell accumulation, localization, and function.
• Assessment of T cell apoptosis and hyporesponsiveness.
• Evaluation of therapeutic interventions (CD40 antibody, TLR7 agonist, IL-2) and non-persisting vaccine formulations.

Main Results:

• Peptide/IFA vaccination led to CD8(+) T cell accumulation at the vaccine site, not tumors.
• T cells at the vaccine site became dysfunctional and underwent apoptosis (programmed cell death) mediated by interferon-γ (IFN-γ) and Fas ligand (FasL).
• Interventions reduced apoptosis but did not prevent T cell sequestration at the vaccine site.
• A non-persisting vaccine formulation promoted T cell localization to tumors, enhancing antitumor activity and memory formation.

Conclusions:

• Persisting vaccine depots sequester and eliminate antigen-specific T cells, hindering effective tumor eradication.
• Short-lived vaccine formulations can overcome these limitations, leading to improved therapeutic outcomes.
• Optimizing vaccine formulation is key to enhancing the efficacy of peptide-based cancer vaccines.